Medtech manufacturers gathered in Amsterdam to discuss the latest innovations for managing diabetes. Here are three highlights from the first day of the conference: 1. Dexcom previews new data for ...

A survey conducted by the continuous glucose monitor maker Dexcom found that just over half of healthcare providers ranked technology and education as having larger impacts when it comes to ...

DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across ...

At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system, 1 showing an overall mean absolute relative difference (MARD) of 8.0% ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Dexcom, the local maker of continuous glucose monitors, received a warning letter from the Food and Drug Administration last week citing issues at two of its manufacturing facilities. The warning ...

Investors with a lot of money to spend have taken a bullish stance on DexCom DXCM. And retail traders should know. We noticed this today when the positions showed up on publicly available options ...

DexCom DXCM received a warning letter from the FDA on March 4, 2025, following inspections of its San Diego and Mesa facilities in 2024. The FDA cited deficiencies in the company’s manufacturing ...